Prof. Dr. Çağlayan Geredeli

• Breast Neoplasms 14 publications
  Source: OpenAlex / PubMed MeSHView publications
• Carcinoma, Non-Small-Cell Lung 9 publications
• Lung Neoplasms 8 publications
• Colorectal Neoplasms 8 publications
• Pancreatic Neoplasms 3 publications
• Brain Neoplasms 3 publications
• Adenocarcinoma 3 publications
• Colonic Neoplasms 2 publications
• Liver Neoplasms 2 publications
• Stomach Neoplasms 2 publications

Medical areas of interest the doctor lists on their own profile on the institution’s website. Source: medicalpark.com.tr.

Experience

• 19941995 Kütahya Gediz Devlet Hastanesimedicalpark.com.tr
• 19951999 Dicle Üniversitesi Tıp Fakültesi Hastanesi İÇ hastalıklarımedicalpark.com.tr
• 20002001 Şırnak Silopi Devlet hastanesi İç Hastalıkları Uzmanı ve Başhekimimedicalpark.com.tr
• 20022003 Ankara Polatlı SSK Hastanesi İç Hatalıkları Uzmanımedicalpark.com.tr
• 20042007 Ankara Polatlı Hayrettin Ekmen Devlet Hastanesi İç Hastalıkları uzmanı ve Başhekimimedicalpark.com.tr
• 20082009 Ankara Polatlı Duatepe Devlet Hastanesi İç Hastalıkları Uzmanı ve Başhekim Yard.medicalpark.com.tr
• 20102012 Necemttin Erbakan Üniversitesi Meram Tıp Fakültesi Tıbbi Onkoloji Bölümümedicalpark.com.tr
• 20132014 Konya Eğitim ve Araştırma Hastanesi Tıbbi Onkoloji Uzmanımedicalpark.com.tr
• 20152017 İstanbul Okmeydanı Eğitim ve Araştırma Hastanesi Tıbbi Onkoloji Uzmanımedicalpark.com.tr
• 20182021 İstanbul Okmeydanı Eğitim ve Araştırma Hastanesi Tıbbi Onkoloji Eğitim görevlisimedicalpark.com.tr
• 20222023 İstanbul Prof Dr. Cemil Taşcıoğlu Şehir Hastanesi Tıbbi Onkoloji Eğitim Sorumlusumedicalpark.com.tr

Education

• Education1994 Selçuk Üniversitesi Tıp Fakültesimedicalpark.com.tr
• Education2012 NEÜ Meram Tıp Fakültesi Tıbbi Onkoloji Uzmanımedicalpark.com.tr
• Education2018 Tıbbi Onkoloji Doçentimedicalpark.com.tr

• SpecialtyMedical Oncologymedicalpark.com.trFrom source
• Department name at the sourceMedikal Onkoloji (Tıbbi Onkoloji)medicalpark.com.trFrom source
• Institutionİstinye Üniversitesi Medical Park Gaziosmanpaşamedicalpark.com.trFrom source
• Area of workBreast NeoplasmsExtracted from 14 publications · Model version —From source
• Publications121 publicationsOpenAlex, ORCIDFrom source
• ORCID0000-0002-3982-7465ORCIDFrom source
• Last synchronised4 November 2026 20:26https://www.medicalpark.com.tr/hekimler/caglayan-geredelimedicalpark.com.tr

1. Real-world practices in RAS wild-type metastatic colorectal cancer patients treated with targeted agents in the first-line a nationwide onco-colon Turkey registry

   Anadolu Kliniği Tıp Bilimleri Dergisi, 2026

   DOI 10.21673/anadoluklin.1675424 Open-access full textSource: OpenAlex

2. The Impact of Concurrent Proton Pump Inhibitors on Nivolumab Response in Metastatic Non-Small Cell Lung Cancer: A Multicenter Real-Life Study

   Medicina, 2026

   DOI 10.3390/medicina62010214 PMID 41597500 Open-access full textSource: OpenAlex

3. Predictors of Recurrence Following Curative-Intent Local Therapy for Oligometastatic Renal Cell Carcinoma: A Multicenter Retrospective Cohort Study from the Turkish Oncology Group (TOG)

   Eurasian Journal of Medical Investigation, 2026

   DOI 10.14744/ejmi.2612571 Source: ORCID

4. KRAS Mutasyonu Saptanmayan Metastatik Kolorektal Kanserli Hastalarda Anti-EGFR Kullanımı-Ulusal Onco-Colon Çalışması Gerçek Yaşam Verleri

   DergiPark (Istanbul University), 2025

   Source: OpenAlex

5. Talazoparib in patients with BRCA mutant metastatic breast or ovarian carcinoma: results of early access program

   BMC Cancer, 2025

   DOI 10.1186/s12885-025-15287-2 PMID 41275151 Open-access full textSource: OpenAlex

6. The Efficiency of Concomitant Antibiotic Usage On Survival Outcomes of Nivolumab-Treated Metastatic Renal Cell Carcinoma Patients: A Multicenter Experience

   Research Square, 2025

   DOI 10.21203/rs.3.rs-6066659/v1 Open-access full textSource: OpenAlex

7. Perioperative 5-fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) regimen in gastric cancer: Pathological regression grade and its relationship to clinical outcome

   Indian Journal of Cancer, 2024

   DOI 10.4103/ijc.ijc_1283_20 PMID 39960699 2 citations (Europe PMC) Open-access full textSource: OpenAlex

8. Real-world treatment outcomes from nationwide Onco-colon Turkey registry in RAS wild-type patients treated with biologics second-line mCRC

   Journal of Oncology Pharmacy Practice, 2024

   DOI 10.1177/10781552241241004 PMID 38613329 Open-access full textSource: OpenAlex

9. Sequential Use of Sorafenib and Regorafenib in Hepatocellular Cancer Recurrence After Liver Transplantation: Treatment Strategies and Outcomes

   Cancers, 2024

   DOI 10.3390/cancers16223880 PMID 39594835 8 citations (Europe PMC) Open-access full textSource: ORCID

10. The impact of body mass index on the progression free survival of CDK 4/6 inhibitors in metastatic breast cancer patients

    Research Square, 2024

    DOI 10.21203/rs.3.rs-4144594/v1 Open-access full textSource: ORCID